Imjudo (tremelimumab) / Pfizer, AstraZeneca  >>  Phase 1
Welcome,         Profile    Billing    Logout  

16 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imjudo (tremelimumab) / AstraZeneca, Pfizer
jRCT2031210046: A phase Ib study of durvalumab (MEDI4736) tremelimumab combined with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion

Suspended
1b
15
Japan
Imfinzi (durvalumab) - AstraZeneca, Imjudo (tremelimumab) - AstraZeneca, Pfizer
Chiba university hospital, AstraZeneca K.K.
Hepatocellular carcinoma
 
 
NCT02071992: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Not yet recruiting
1
24
US
Tremelimumab, CP-675,206, Ticilimumab, MEDI3617, MEDI-3617
F. Stephen Hodi, MD, MedImmune LLC
Metastatic Melanoma
06/17
02/19
NCT02537418: Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Active, not recruiting
1
153
Canada
durvalumab, tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Solid Malignancies
07/18
12/24
NCI-2018-01189, NCT03132467: Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Completed
1
16
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
01/19
05/24
NCT03275597: Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Terminated
1
17
US
Durvalumab, 1428935-60-7, D10808, Tremelimumab, 745013-59-6, QEN1X95CIX, Stereotactic Body Radiotherapy, SRBT, stereotactic ablative radiotherapy, SABR
University of Wisconsin, Madison, AstraZeneca
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
07/20
07/20
NCT02141542: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Hourglass Jan 2017 - Dec 2017 : Tremelimumab and MEDI3617 combination in unresectable melanoma
Completed
1
15
US
Tremelimumab, CP-675,206, Ticilimumab, MEDI3617, MEDI-3617
F. Stephen Hodi, MD, MedImmune LLC
Metastatic Melanoma
09/20
09/20
CLOVER, NCT03509012: Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Hourglass Nov 2021 - Dec 2021 : From CLOVER trial in combination with tremelimumab for solid tumors
Active, not recruiting
1
105
Europe, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
AstraZeneca
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
12/20
12/24
NCT03923270: Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Active, not recruiting
1
25
US
Durvalumab, Imfinzi, MEDI4736, Tremelimumab, Olaparib Pill, Lynparza, MK-7339, Thoracic Radiotherapy
H. Lee Moffitt Cancer Center and Research Institute, AstraZeneca
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
06/23
06/24
NCT05928962: An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Enrolling by invitation
1
10
RoW
Recombinant Human Adenovirus Type 5 Injection, Tremelimumab
Fujian Cancer Hospital
Malignant Melanomas
08/23
10/24
NCT03452332: Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Completed
1
20
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Metastatic Vaginal Adenocarcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Recurrent Cervical Adenocarcinoma, Recurrent Cervical Carcinoma, Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Adenocarcinoma, Vulvar Squamous Cell Carcinoma
08/23
08/23
NCT02639026: Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Completed
1
53
US
Radiotherapy, MEDI4736, Tremelimumab
Abramson Cancer Center at Penn Medicine
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
06/23
06/23
NCT04605731: Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Recruiting
1
32
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
City of Hope Medical Center, National Cancer Institute (NCI)
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/24
RESOLVE, NCT05154994: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma

Suspended
1
9
US
Belinostat, Beleodaq, PXD 101, PXD101, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
University of Utah, National Cancer Institute (NCI)
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
11/24
11/26
NCT02812420: Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Active, not recruiting
1
54
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Therapeutic Conventional Surgery, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
12/24
12/24
RAIDEN, NCT06058663: Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
1
18
US
Angiography, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Imjudo, Ticilimumab, Tremelimumab-actl, Yttrium-90 Microsphere Radioembolization, Yttrium Y 90 Microsphere Therapy, Yttrium-90 Radioembolization
Mayo Clinic, National Cancer Institute (NCI)
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
11/25
11/25
NCT05701488: SIRT With Tremelimumab and Durvalumab for Resectable HCC

Recruiting
1
20
US
Durvalumab, Imjudo, MEDI4736, Tremelimumab, Imfinzi, SIRT, Selective Internal Yttrium-90 Radioembolization
Jiping Wang, MD, PhD, AstraZeneca, Sirtex Medical
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
10/25
10/25

Download Options